Loading asset research
Foghorn Therapeutics Inc. Common Stock
FHTXNasdaq · USD · StocksQuote as of · Exchange session not verified$4.41
-1.89%
Today
FHTX
Loading 1D prices…
Market cap
$262.5M
Volume
289.1K
52w high
$7.6152w low
$3.27Company profile
Foghorn Therapeutics Inc. Common Stock
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Watertown, MA, United States
Employees
106
Fiscal year end
1231
CIK
1822462
Session & valuation
Open$4.54
Previous close$4.49
Day high$4.62
Day low$4.37
30-day avg. volume345.5K
Outstanding shares59.4M
Diluted EPS-$1.18
Latest annual period
P/E (trailing)-3.73
P/E (forward)-4.05
Price / book-3.20
Beta2.86
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PRQRProQR Therapeutics N.V. Ordinary Shares | $262.5M | — | — | -$0.40 | -3.61% | Buy |
| AKBAAkebia Therapeutics Inc. Common Stock | $263.7M | $236.2M | -2.24% | -$0.02 | +0.84% | Buy |
| TRDAEntrada Therapeutics Inc. Common Stock | $264.8M | $25.4M | -565.48% | -$3.47 | +6.07% | Buy |
| CAMPCAMP4 Therapeutics Corporation Common Stock | $266.7M | $3.5M | -2298.54% | -$2.65 | -1.61% | Buy |
| PYXSPyxis Oncology Inc. Common Stock | $267.7M | $13.9M | -574.55% | -$1.28 | -1.83% | Buy |